X4 Pharmaceuticals Inc. (XFOR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

X4 Pharmaceuticals Inc. (XFOR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.46

-0.11 (-18.63%)

At close: Jan 14, 2025, 3:59 PM

0.48

4.33%

Pre-market Jan 15, 2025, 08:45 AM EST

undefined% (undefined)

Bid	0.46
Market Cap	78.45M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.08
PE Ratio (ttm)	-5.75
Forward PE	n/a
Analyst	Buy

Ask	0.49
Volume	3,683,018
Avg. Volume (20D)	3,672,408
Open	0.57
Previous Close	0.57
Day's Range	0.46 - 0.57
52-Week Range	0.26 - 1.60
Beta	undefined

About XFOR

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and my...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 16, 2017

Employees 127

Stock Exchange NASDAQ

Ticker Symbol XFOR

Website https://www.x4pharma.com

Analyst Forecast

According to 3 analyst ratings, the average rating for XFOR stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 769.57% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

X4 Pharmaceuticals Inc. is scheduled to release its earnings on Mar 20, 2025, before market opens.
Analysts project revenue of $3.94M, reflecting a n/a YoY growth and earnings per share of -0.16, making a 60.00% increase YoY.

Why Price Moved

2 months ago · Source

+47.85%

X4 Pharmaceuticals shares are trading higher. Stif... Unlock content with Pro Subscription

2 months ago · Source

-53.17%

X4 Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

2 months ago · seekingalpha.com

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Christophe Arbet-Engels...